ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.…
ClearPoint Neuro, Inc. Q3 2026 Earnings Call Summary
ClearPoint Neuro (NASDAQ: CLPT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 172 employees.
The shares were at 6.910 USD on 20 November 2026, down 56.3% over 52 weeks. Its 52-week range is 6.850 USD to 19.63 USD, and it trades at the bottom of that range.
Its market capitalisation is 221.49M USD.
ClearPoint Neuro reports return on equity of -91.1%, an operating margin of -66.6% and revenue up 36.3% year over year.
Its debt exceeds its cash by 27.52M USD, a debt-to-equity ratio of 2.08. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 21.50 USD is 211.1% above the current price. The next earnings report is expected on 17 March 2027.